Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy

NCT03731260 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT03731260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03731260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Lead sponsor
Blueprint Medicines Corporation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 16, 2019
Completion date
June 23, 2027
Enrollment
251 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

indolent systemic mastocytosis